TNF and psoriasis: A multicenter case series involving 10 patients (4 females and 6 males; 2 patients also had CD) with moderate-to-severe HS (9 of whom had received anti-TNF-α therapy, and 1 patient was biologic-naïve) treated with ustekinumab at psoriasis dosage, reported (after a median treatment duration of 48 weeks) a reduction of at least 1 point in HS-PGA and a decrease of ≥2 points in the Numerical Pain Rating Scale (NPRS) in 70% and 80% of patients, respectively.